The SOC treatment regimen (5 days) was not altered to match the, initially approved, 3 day Brilacidin co-treatment. SOC remained constant, hence SOC. The difference now, following the scheduled pause and safety validation, is an approved increase of the Brilacidin dose from 3 to 5 days.
Hopefully, the additional testing sites will ensure the trial is completed to schedule.
Efficacy is our next hurdle.
(5)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links